Biocon said it will submit a comprehensive corrective and preventive action (CAPA) plan within the stipulated timeline and is ...

Biocon shares jump 8% post Q4 results. Is the Street happy? Biocon's shares surged by 8% on Tuesday due to strong Q4 earnings ...

Biocon Limited has announced that the United States Food and Drug Administration (USFDA) has completed a Pre-License ...

Bengaluru/Toronto: Biocon is stepping up its global biosimilars play with fresh approvals in Canada, targeting large patient ...

Denosumab therapies are used to increase bone mass and treat osteoporosis, as well as address bone complications in cancer.

At around 10:42 a.m., Biocon shares were up 1.51 per cent, or Rs 3.6, at Rs 242.05 apiece on BSE. The market capitalisation ...

Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to ...

Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™ (Denosumab biosimilars to Prolia® and Xgeva®) for bone health.